Literature DB >> 11370797

Sexual dysfunction in hypertensive patients treated with losartan.

J L Llisterri1, J V Lozano Vidal, J Aznar Vicente, M Argaya Roca, C Pol Bravo, M A Sanchez Zamorano, C M Ferrario.   

Abstract

BACKGROUND: Impaired erectile function in men is a component of the dysmetabolic syndrome of high blood pressure as well as a sequela of antihypertensive therapy. This prospective interventional study in men with uncontrolled hypertension (blood pressure > or =140/90 mm Hg) used a survey instrument to assay sexual dysfunction before and after therapy with losartan.
METHODS: We evaluated the influence of a 12-week therapy with losartan in 82 hypertensive subjects with (n = 82) and without (n = 82) a diagnosis of erectile dysfunction using a self-administered questionnaire validated in another 60 subjects with hypertension.
RESULTS: From an initial sample of 323 hypertensive men and women, 82 men, aged 30 to 65 years, with sexual dysfunction underwent a 12-week regimen of losartan therapy (50-100 mg/day). Losartan treatment improved sexual satisfaction from an initial 7.3 to 58.5% (chi2; P = 0.001). Subjects reporting a high frequency of sexual activity improved from 40.5% initially to 62.3% after drug treatment, whereas the number of patients with low or very low frequency of sexual activity decreased significantly (chi2; P = 0.001). At the completion of the 12-week losartan regimen, only 11.8% of the treated subjects reported in improvement in sexual function. Improvement on quality of life was demonstrated in 73.7% of subjects medicated with losartan, 25.5% reported no changes, and only 0.8% felt worse. In the group without sexual dysfunction, losartan had a nonsignificant effect on sexual function.
CONCLUSIONS: Our data suggest that losartan improved erectile function and both satisfaction and frequency of sexual activity. Because side effects are one of the most influential factors in the management of hypertension, an added benefit of losartan therapy may be its positive impact on quality of life.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11370797     DOI: 10.1097/00000441-200105000-00006

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  25 in total

Review 1.  Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs.

Authors:  Rainer Düsing
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Effects of antihypertensive therapy on sexual activity in hypertensive men.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 3.  Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.

Authors:  Jay Pravin Patel; Eric Hweegeun Lee; Carlos Ignacio Mena-Hurtado; Charles N Walker
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

Review 4.  Management of erectile dysfunction in hypertension: Tips and tricks.

Authors:  Margus Viigimaa; Charalambos Vlachopoulos; Antonios Lazaridis; Michael Doumas
Journal:  World J Cardiol       Date:  2014-09-26

Review 5.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  A population-based, longitudinal study of erectile dysfunction and future coronary artery disease.

Authors:  Brant A Inman; Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Ajay Nehra; Michael M Lieber; Véronique L Roger; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 7.  Erectile dysfunction: symptom or disease?

Authors:  C Foresta; N Caretta; A Aversa; C Bettocchi; G Corona; S Mariani; M Rossato
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

Review 8.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

9.  The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.

Authors:  Ajay Nehra; Graham Jackson; Martin Miner; Kevin L Billups; Arthur L Burnett; Jacques Buvat; Culley C Carson; Glenn R Cunningham; Peter Ganz; Irwin Goldstein; Andre T Guay; Geoff Hackett; Robert A Kloner; John Kostis; Piero Montorsi; Melinda Ramsey; Raymond Rosen; Richard Sadovsky; Allen D Seftel; Ridwan Shabsigh; Charalambos Vlachopoulos; Frederick C W Wu
Journal:  Mayo Clin Proc       Date:  2012-08       Impact factor: 7.616

Review 10.  Antihypertensive treatment and sexual dysfunction.

Authors:  Athanasios Manolis; Michael Doumas
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.